Table 1 Univariable Cox proportional hazards model
From: Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
| Â | HR | 95% CI | P-value |
|---|---|---|---|
Stage (per stage increment) | 1.92 | 1.43–2.59 | 1.63E-05 |
Age (per 1-yr increment) | 1.03 | 1.01–1.05 | 2.40E-04 |
AI treatment (vs. no AI treatment) | 0.68 | 0.45–1.05 | 0.0812 |
Post-menopausal (vs. pre-menopausal) | 1.52 | 0.94–2.45 | 0.0913 |
Tamoxifen treatment (vs. no tamoxifen treatment) | 0.67 | 0.42–1.07 | 0.0921 |